Palisade Bio, Inc.
PALI- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001357459
In the last 90 days, Palisade Bio, Inc. insiders filed 3 open-market purchases and 2 sales; 124 institutions reported holding it in 13F filings for Q2 2026, worth $362.4M in total; no superinvestor holds it.
Q3 2022 vs. Q2 2022
How the institutions holding Palisade Bio, Inc. changed between Q2 2022 and Q3 2022.
All holders in Q3 2022All holders in Q2 2022
| Measure | Q2 2022 | Q3 2022 | Change |
|---|---|---|---|
| Holders | 26 | 33 | +7 |
| Shares | 971.5K | 8.40M | +7.43M (+764.9%) |
| Value | $395.0K | $842.0K | +$447.0K (+113.2%) |
New holders (9)
Institutions that held Palisade Bio, Inc. at the end of Q3 2022 but not at the end of Q2 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Altium Capital Management LP | 5,643,007 | $559.0K | 0.21% |
| Sabby Management, LLC | 445,899 | $44.0K | 0.10% |
| Warberg Asset Management LLC | 150,000 | $15.0K | 0.00% |
| Virtu Financial LLC | 109,321 | $11.0K | 0.00% |
| Two Sigma Investments, LP | 80,338 | $8.00K | 0.00% |
| Citadel Advisors LLC | 28,299 | $3.00K | 0.00% |
| FMR LLC | 20,135 | $2.00K | 0.00% |
| Cetera Advisor Networks LLC | 21,642 | $2.00K | 0.00% |
| Buckingham Strategic Partners | 10,000 | $1.00K | 0.00% |
Sold out (2)
Institutions that held Palisade Bio, Inc. at the end of Q2 2022 and filed for Q3 2022 without it.
| Institution | Shares, Q2 2022 | Value, Q2 2022 |
|---|---|---|
| Strategic Wealth Designers | 53,129 | $22.0K |
| Sterling Investment Advisors, Ltd. | 5 | $0 |